ABBV - AbbVie Inc.

NYSE - NYSE Delayed Price. Currency in USD

AbbVie Inc.

1 North Waukegan Road
North Chicago, IL 60064
United States
847-932-7900
http://www.abbvie.com

SectorHealthcare
IndustryDrug Manufacturers - Major
Full Time Employees30,000

Key Executives

NameTitlePayExercisedYear Born
Mr. Richard A. GonzalezChairman & CEO6.54MN/A1954
Dr. Michael E. SeverinoVice Chairman & Pres3.07MN/A1966
Mr. Robert A. MichaelExec. VP & CFO1.54MN/A1970
Ms. Laura J. SchumacherVice Chairman of External Affairs, Chief Legal Officer & Corp. Sec.3.52M3.97M1963
Mr. Carlos AlbanVice Chairman & Chief Commercial Officer3.19M4.09M1963
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; and Cystic Fibrosis Foundation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Corporate Governance

AbbVie Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 9; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.